Attention Deficit Hyperactivity Disorder Drugs Market | Leading Segments, Trends, Drivers and Challenges
Eli Lilly and Co., Glenmark Pharmaceuticals Ltd., Johnson and Johnson Inc., Novartis AG, Purdue Pharma LP are some of the key market vendors
Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market is likely to post an incremental growth of $ 9.61 billion, accelerating at a CAGR of 9.06% during the forecast period. This research provides a detailed analysis of the market segments and geographic landscape. It also offers insights into the various growth factors and challenges that are likely to have a negative impact on market growth. This thorough research will equip clients with the insights necessary to plan and strategize a post-pandemic recovery plan.
Request for Our Free Sample Report for detailed Insights
Attention Deficit Hyperactivity Disorder Drugs Market: Market Segments and Growth Forecasts
This research report will provide insights into the current market share of each segment along with growth projections for the next five years.
- Market is segmented by Product (stimulants and non-stimulants) and Geography (North America, Europe, Asia, and ROW). Market growth by the stimulants segment will be significant during the forecast period as the use of stimulants is approved by the US FDA for use in children and adults and they are considered gold standards for the treatment of ADHD.
- 40% of the market growth will originate from North America during the forecast period. The US and Canada are the key markets for ADHD drugs in North America owing to the rise in the attentiveness of parents toward children with ADHD, approval & commercialization of drugs, and increase in the number of clinical trials in the region. However, the market growth rate in this region will be slower than the growth of the market in Asia and Europe where the awareness and treatment of this disorder is steadily increasing.
- This report provides an accurate prediction of the contribution of all the geographic segments to the growth of the Attention Deficit Hyperactivity Disorder Drugs Market size.
Attention Deficit Hyperactivity Disorder Drugs Market: Trends, Drivers, Challenges
The report also offers a detailed impact analysis of various trends, drivers, and challenges that are likely to influence the market growth during the forecast period.
- ADHD treatment market is currently witnessing significant increase in government initiatives to promote awareness and to fund drug development in the area of mental health therapeutics. Several government bodies such as the US Department of Health and Human Services (HHS) and National Health Service (NHS) England are investing in creating awareness as well as therepeutics for ADHD.
- Increasing expenditure on prescription drugs will be instrumental in driving market growth during the forecast period.
- Lack of proper diagnostic criteria for ADHD in adults is a hurdle that needs to be crossed on the path to success. The use of screening tools and informed applications such as DSM-IV, brochures, and the cultivation of consultation and referral services can help physicians significantly augment the diagnosis and treatment of adults with ADHD.
Attention Deficit Hyperactivity Disorder Drugs Market: Vendor Analysis
- The market is fragmented.
- Aurobindo Pharma Ltd., Aytu BioPharma Inc., Eli Lilly and Co., Glenmark Pharmaceuticals Ltd., Johnson and Johnson Inc., Novartis AG, Purdue Pharma LP, SHIONOGI Co. Ltd., Takeda Pharmaceutical Co. Ltd., and Tris Pharma Inc. are some of the major market participants.
- The unprecedented outbreak of COVID-19 in 2020 has had a significant impact on market segments had a ripple effect on various stakeholders. Our vendor analysis and insights will provide you with all the information required to make the most of the opportunities and plan business recovery and growth post the pandemic.
Key Areas Covered in our Report:
- Attention Deficit Hyperactivity Disorder Drugs Market Split by Product
- Stimulants
- Non-stimulants
- Attention Deficit Hyperactivity Disorder Drugs Market Split by Geography
- North America
- Europe
- Asia
- ROW
Customer landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- APAC - Market size and forecast 2020-2025
- MEA - Market size and forecast 2020-2025
- Europe - Market size and forecast 2020-2025
- North America - Market size and forecast 2020-2025
- South America - Market size and forecast 2020-2025
- Key leading countries
- Market opportunity by geography
- Market drivers
- Market challenges
- Market trends
Vendor Landscape
- Competitive scenario
- Vendor landscape
- Landscape disruption
Vendor Analysis
- Aurobindo Pharma Ltd.
- Aytu BioPharma Inc.
- Eli Lilly and Co.
- Glenmark Pharmaceuticals Ltd.
- Johnson and Johnson Inc.
- Novartis AG
- Purdue Pharma LP
- SHIONOGI Co. Ltd.
- Takeda Pharmaceutical Co. Ltd.
- Tris Pharma Inc.
For more insights into this market: Download a Free Sample Report. Our custom reports provide market insights at the global and regional level along with pipeline analysis of new product launches. It also provides a peek into the latest R&D along with an impact analysis of government regulations.
The report provides insights into the following FAQs:
- What is the market CAGR?
The market will accelerate at a CAGR of 9.06%.
- What is the incremental growth of the market?
The market is expected to grow by $ 9.61 bn through 2021-2025.
- What is a key factor driving this market?
Rising government support will drive market growth over the forecast period.
- What are the key regions covered in this market research report?
North America, Europe, Asia, and ROW are the key regions featured in this research report.
- Which is the leading geographic region for this market:
40% growth will originate from North America
- Who are the leading market vendors?
The leading vendors in this market are Aurobindo Pharma Ltd., Aytu BioPharma Inc., Eli Lilly and Co., Glenmark Pharmaceuticals Ltd., Johnson and Johnson Inc., Novartis AG, Purdue Pharma LP, SHIONOGI Co. Ltd., Takeda Pharmaceutical Co. Ltd., and Tris Pharma Inc.
- What are the market segments covered in this report?
The market is segmented by Product (stimulants and non-stimulants) and Geography (North America, Europe, Asia, and ROW)
